*Health Economics of Renal Replacement Therapy DOI: http://dx.doi.org/10.5772/intechopen.111526*

#### **Table 4.**

*Composition of the target population.*

**Figure 7.** *Comparison of survival rates between marginal and standard donor groups (Kaplan-Meier curve).*

influencing cost-effectiveness (**Table 5**). No statistically significant difference was observed in the analysis in which the conditions for setting the standard donor group were stricter and the age at transplantation and dialysis history were the same for both groups (**Table 6**).


#### **Table 5.**

*Factors affecting cost-effectiveness (multiple regression analysis).*


*(Note) Units in the table are eGFR: mL/min/1.73m2 , age: years old, and BMI: kg/m2 Supplement: SD notation.*

#### **Table 6.**

*Cost-effectiveness analysis with more detailed conditions for standard donors. (source: Ref. [19]).*

The results of this study showed that the survival and cost-effectiveness in the marginal donor group were not significantly lower than those in the standard donor group. These results are generally valid in the clinical settings in Japan, where the practice of marginal donors is expanding while maintaining the clinical results of kidney transplantation. In the future, along with a robust evaluation by non-inferiority trials, continuous (prospective) verification of long-term results using high-quality research designs, such as randomized trials, will be essential.
